-
1.发明授权Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents 有权丙型肝炎病毒基因型的序列及其作为治疗和诊断剂的用途公开(公告)号：US07255997B1
公开(公告)日：2007-08-14
申请号：US09638693
申请日：2000-08-15
申请人： Geert Maertens , Lieven Stuyver
发明人： Geert Maertens , Lieven Stuyver
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C12N2770/24222
摘要： The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 region of HCV type 3; and/or the region spanning positions 4664 to 4730 of the NS3 region of HCV type 3; and/or the region spanning positions 4892 to 5292 of the NS3/4 region of HCV type 3; and/or the region spanning positions 8 023 to 8 235 of the NS5 region of the BR36 subgroup of HCV type 3a; and/or the coding region of HCV type 4a starting at nucleotide 379 in the core region; and/or the coding region of HCV type 4; and/or the coding region of HCV type 5, with said nucleotide numbering being with respect to the numbering of HCV nucleic acids as show in Table 1, and with said polynucleic acids containing at least one nucleotide difference with known HCV type 1, and/or HCV type 2 genomes in the above-indicated regions, or the complement thereof.
摘要翻译： 本发明涉及包含至少一种含有8个或更多个连续核苷酸的多核苷酸的多核酸组合物，其对应于来自HCV 3型核心/ E1区域的位置417至957的区域的核苷酸序列; 和/或跨越HCV 3型NS3区域的位置4664至4730的区域; 和/或跨越HCV 3型NS3 / 4区的位置4892至5292的区域; 和/或跨越HCV3a型BR36亚组的NS5区域的位置8 023至8 235的区域; 和/或从核心区域的核苷酸379开始的HCV型4a的编码区; 和/或HCV 4型的编码区; 和/或HCV 5型的编码区，其中所述核苷酸编号相对于表1所示的HCV核酸的编号，并且所述多核苷酸与已知的HCV I型具有至少一个核苷酸差异，和/ 或上述区域中的HCV 2型HCV基因组，或其补体。
-
2.发明授权Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents 有权丙型肝炎病毒基因型的序列及其作为治疗和诊断剂的用途公开(公告)号：US07122306B2
公开(公告)日：2006-10-17
申请号：US09873224
申请日：2001-06-05
申请人： Geert Maertens , Lieven Stuyver
发明人： Geert Maertens , Lieven Stuyver
IPC分类号： C12Q1/68
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C12N2770/24222
摘要： The present application provides polynucleic acid sequences of 8 or more contiguous nucleotides selected from an HCV subtype 3c genomic sequence selected from the region spanning positions 1 to 957 of the Core of Core/E1 region of HCV subtype 3c, wherein said polynucleic acid sequence is capable of hybridizing to HCV type 3c, but not another type or subtype of HCV; or the complement of the polynucleic acid, wherein the polynucleic acid contains at least one genotype-specific nucleotide. Methods and means of using and making the described sequences are also provided.
摘要翻译： 本申请提供了选自HCV亚型3c基因组序列中的8个或更多个连续核苷酸的多核酸序列，所述HCV亚型3c基因组序列选自HCV亚型3c核心/ E1区核心的1至957位核苷酸的区域，其中所述多核酸序列 能够与HCV 3型HCV杂交，但不能与HCV的另一类型或亚型杂交; 或多核酸的互补物，其中所述多核酸含有至少一种基因型特异性核苷酸。 还提供了使用和制作所述序列的方法和手段。
-
3.发明申请Multi-mer peptides derived from hepatitis C virus envelope proteins for diagnostic use and vaccination purposes 审中-公开衍生自丙型肝炎病毒包膜蛋白的多聚体肽用于诊断用途和疫苗接种目的公开(公告)号：US20040126754A1
公开(公告)日：2004-07-01
申请号：US10685435
申请日：2003-10-16
发明人： Geert Maertens , Erik Depla
IPC分类号： C12Q001/70 , C07K016/08 , C07K014/02
CPC分类号： C07K14/005 , A61K39/00 , C12N2770/24222 , G01N33/56983 , G01N2500/00
摘要： Multimer peptides (e.g. 30- to 45-mer peptides) derived from hepatitis C virus envelope proteins reacting with the majority of anti-HCV antibodies present in patient sera are described. The usage of the latter peptides to diagnose, and to vaccinate against, an infection with hepatitis C virus is also disclosed.
摘要翻译： 描述了源自患有血清中存在的大多数抗HCV抗体的丙型肝炎病毒包膜蛋白的多聚体肽（例如30-45聚体肽）。 还公开了后一种肽用于丙型肝炎病毒感染的诊断和疫苗接种。
-
4.发明申请Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents 有权丙型肝炎病毒基因型的序列及其作为治疗和诊断剂的用途公开(公告)号：US20030064360A1
公开(公告)日：2003-04-03
申请号：US09873224
申请日：2001-06-05
发明人： Geert Maertens , Lieven Stuyver
IPC分类号： C12Q001/70 , C07H021/04 , C12N007/00 , C12P021/02 , C12N005/06 , C12N015/86
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C12N2770/24222
摘要： The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 region of HCV type 3; and/or the region spanning positions 4664 to 4730 of the NS3 region of HCV type 3: and/or the region spanning positions 4892 to 5292 of the NS3/4 region of HCV type 3; and/or the region spacing positions 8023 to 8235 of the NS5 region of the BR36 subgroup of HCV type 3a; and/or the coding region of HCV type 4a starting at nucleotide 379 in the core region; and/or the coding region of HCV type 4; and/or the coding region of HCV type 5, with said nucleotide numbering being with respect to the numbering of HCV nucleic acids as shown in Table 1, and with said polynucleic acids containing at least one nucleotide difference with known HCV type 1, and/or HCV type 2 genomes in the above-indicated regions, or the complement thereof.
摘要翻译： 本发明涉及包含至少一种含有8个或更多个连续核苷酸的多核苷酸的多核酸组合物，其对应于来自HCV 3型核心/ E1区域的位置417至957的区域的核苷酸序列; 和/或跨越HCV 3型NS3区域的位置4664至4730的区域和/或跨越HCV 3型NS3 / 4区域的位置4892至5292的区域; 和/或HCV3型BR36亚组的NS5区域的区域间隔位置8023至8235; 和/或从核心区域的核苷酸379开始的HCV型4a的编码区; 和/或HCV 4型的编码区; 和/或HCV 5型的编码区，其中所述核苷酸编号相对于表1所示的HCV核酸的编号，并且所述多核苷酸与已知的HCV I型具有至少一个核苷酸差异，和/ 或上述区域中的HCV 2型HCV基因组，或其补体。
-
5.发明申请Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications 审中-公开针对微管相关蛋白tau的单克隆抗体，分泌这些抗体的杂交瘤，这些单克隆抗体的抗原识别及其应用公开(公告)号：US20020001857A1
公开(公告)日：2002-01-03
申请号：US09790148
申请日：2001-02-21
IPC分类号： G01N033/531 , C12P021/04
CPC分类号： C07K16/18 , C07K14/4711 , C07K2317/34 , Y10S436/811
摘要： The invention relates to a monoclonal antibody which forms an immunological complex with an epitope of an antigen belonging to normal human tau protein as well as abnormally phosphorylated human tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from human cerebral cortex. The monoclonal antibodies of the invention can be used to detect tau and abnormally phosphorylated tau in brain extracts and in unconcentrated cerebrospinal fluid.
摘要翻译： 本发明涉及与属于正常人tau蛋白的抗原的表位以及异常磷酸化的人tau蛋白形成免疫复合物的单克隆抗体，所述tau蛋白易于从脑匀浆获得，其自身从 人类大脑皮层。 本发明的单克隆抗体可用于检测脑提取物和未浓缩脑脊液中的tau和异常磷酸化tau。
-
6.发明授权Hepatitis C virus peptides obtained from the NS4 coding region and their use in diagnostic assays 失效从NS4编码区获得的丙型肝炎病毒肽及其在诊断测定中的应用
公开(公告)号：US6165730A
公开(公告)日：2000-12-26
申请号：US723425
申请日：1996-09-30
申请人： Robert De Leys
发明人： Robert De Leys
IPC分类号： A61K39/21 , A61K39/29 , A61P31/12 , A61P31/14 , A61P31/18 , A61P37/04 , C07D495/04 , C07K1/00 , C07K1/04 , C07K1/06 , C07K1/10 , C07K1/113 , C07K1/13 , C07K1/14 , C07K7/00 , C07K7/06 , C07K7/08 , C07K14/00 , C07K14/15 , C07K14/155 , C07K14/16 , C07K14/18 , C07K14/655 , C07K16/00 , C07K19/00 , G01N33/53 , G01N33/531 , G01N33/569 , G01N33/576 , G01N33/68
CPC分类号： C07K1/13 , C07K14/005 , C07K2319/00 , C12N2740/14022 , C12N2740/16122 , C12N2770/24222 , G01N33/531 , G01N33/56983 , G01N33/56988 , G01N33/6878 , G01N2333/18
摘要： The etiological agent responsible for non-A, non-B hepatitis has been identified and termed hepatitis C virus (HCV). The HCV genome is a linear, positive-stranded RNA molecule with a length of approximately 9,400 nucleotides. With the exception of rather short untranslated regions at the termini, the genome consists of one large, uninterrupted, open reading frame encoding a polyprotein of approximately 3,000 amino acids. This polyprotein has been shown to be cleaved co-translationally into individual viral structural and non-structural (NS) regions. The structural protein region is further divided into capsid (Core) and envelope (E1 and E2) regions. The NS regions are divided into NS-1 to NS-5. The present invention is directed toward peptides derived from the HCV NS4 region that contain immunologically important epitopes. A series of biotinylated peptides were prepared by solid phase peptide synthesis and these peptides have proven useful for the detection of HCV-specific antisera.
摘要翻译： PCT No.PCT / EP93 / 00517 Sec。 一九九二年四月二十九日 102（e）日期1992年4月29日PCT 1993年3月8日PCT公布。 出版物WO92 / 22571 日期1992年12月23日负责非A非乙型肝炎的病原体已被鉴定，称为丙型肝炎病毒（HCV）。 HCV基因组是长度约为9,400个核苷酸的线性正链RNA分子。 除了末端相当短的非翻译区域外，基因组由编码约3,000个氨基酸的多蛋白的一个大的，不间断的开放阅读框组成。 已经显示该多聚蛋白共同翻译成单独的病毒结构和非结构（NS）区域。 结构蛋白区域进一步分为衣壳（核心）和包膜（E1和E2）区域。 NS区分为NS-1〜NS-5。 本发明涉及源自含有免疫学上重要的表位的HCV NS4区的肽。 通过固相肽合成制备了一系列生物素化肽，这些肽已被证明可用于检测HCV特异性抗血清。
-
公开(公告)号：US6010913A
公开(公告)日：2000-01-04
申请号：US403917
申请日：1995-01-19
CPC分类号： C07K16/18 , C07K14/4711 , C07K2317/34 , Y10S436/811
摘要： The invention deals with isolated human tau peptide epitopes of SEQ ID Nos: 1 to 4, 7 and 15 to 20 which have the capability of binding AT120 monoclonal antibody.
摘要翻译： 本发明涉及具有结合AT120单克隆抗体的能力的SEQ ID NO：1至4,7和15至20的分离的人tau肽表位。
-
公开(公告)号：US5883238A
公开(公告)日：1999-03-16
申请号：US532727
申请日：1995-10-23
申请人： Marc Andrien , Etienne Dupont , Rudi Rossau , Ilse De Canck
发明人： Marc Andrien , Etienne Dupont , Rudi Rossau , Ilse De Canck
CPC分类号： C12Q1/6881 , C12Q2600/156
摘要： The invention relates to a method for typing or subtyping one or more HLA-B alleles characterized by the sequence GCCA at position 30 to 33 of exon 2 (with said numbering being according to Zemmour and Parham, 1992), liable to be present in a sample, with said method comprising at least the following steps: (i) amplifying HLA-B alleles with at least one 5' end amplification primer selected from the following list: 5' -AGGTATTTCTACCCGCCA-3' (B25P) or sequence variants thereof, in combination with an appropriate 3' end primer being chosen from the same alleles as the above defined 5' end primers, with said 5' and 3' end primers being possibly labelled; and, (ii) hybridizing the amplified product, being labelled during or after amplification, at appropriate conditions with one or more suitable probes selected from region 15 to 261 of the HLA-B exon 2 region, with said numbering being according to Zemmour and Parham 1992, (iii) washing at appropriate washing conditions, (iv) detecting the hybrids formed; and, (v) inferring the allele present from the observed hybridization pattern.
摘要翻译： PCT No.PCT / EP94 / 00654 Sec。 371日期1995年10月23日第 102（e）日期1995年10月23日PCT 1994年3月7日PCT公布。 公开号WO94 / 21818 日期1994年9月29日本发明涉及一种用于分类或分型一种或多种HLA-B等位基因的方法，其特征在于外显子2的第30至33位的序列GCCA（所述编号根据Zemmour和Parham，1992）， 所述方法至少包括以下步骤：（i）用选自以下列表的至少一个5'末端扩增引物扩增HLA-B等位基因：5'-AGGTATTTCTACCCGCCA-3'（B25P） 或其序列变体，与合适的3'末端引物组合，其选自与上述定义的5'末端引物相同的等位基因，所述5'和3'末端引物可能被标记; 和（ii）将扩增产物杂交，在适当的条件下用一种或多种选自HLA-B外显子2区域的区域15至261的合适探针进行标记，其中所述编号根据Zemmour和Parham （iii）在适当的洗涤条件下洗涤，（iv）检测所形成的杂交体; 和（v）从观察到的杂交模式推断存在的等位基因。
-
公开(公告)号：US5861257A
公开(公告)日：1999-01-19
申请号：US389011
申请日：1995-02-15
CPC分类号： C07K16/18 , C07K14/4711 , C07K2317/34 , Y10S436/811
摘要： The invention relates to a monoclonal antibody which forms an immunological complex with an epitope of an antigen belonging to normal human tau protein as well as abnormally phosphorylated human tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from human cerebral cortex. The monoclonal antibodies of the invention can be used to detect tau and abnormally phosphorylated tau in brain extracts and in unconcentrated cerebrospinal fluid.
-
10.发明授权Peptides and proteins, process for their preparation and their use as cholesterol acceptors 失效肽和蛋白质，其制备方法及其作为胆固醇受体的用途
公开(公告)号：US5733879A
公开(公告)日：1998-03-31
申请号：US351423
申请日：1994-12-23
CPC分类号： C07K7/08 , C07K14/775 , A61K38/00
摘要： The subject invention relates to amino acid sequences derived from peptide (Glu.sup.1,8, Leu.sup.11,17) 18A, comprising: Glu-Trp-Leu-A-Ala-B-Tyr-C-Lys-Val-D-Glu-Lys-Leu-Lys-Glu-Leu-Phe, wherein A is Lys, Glu or Asp; B is Phe, Glu or Asp; C is Glu, Lys or Arg; and D is Leu, Glu or Asp. The amino acid sequences form complexes with phospholipids, and are useful for the treatment of cardiovascular disease.
摘要翻译： PCT No.PCT / EP93 / 01444 Sec。 371日期1994年12月23日第 102（e）日期1994年12月23日PCT提交1993年6月8日PCT公布。 公开号WO93 / 25581 日期1993年12月23日本发明涉及衍生自肽（Glu1,8，Leu11,17）18A的氨基酸序列，其包含：Glu-Trp-Leu-A-Ala-B-Tyr-C-Lys-Val-D -Glu-Lys-Leu-Lys-Glu-Leu-Phe，其中A为Lys，Glu或Asp; B是Phe，Glu或Asp; C是Glu，Lys或Arg; D为Leu，Glu或Asp。 氨基酸序列与磷脂形成复合物，可用于治疗心血管疾病。
-
-
-
-
-
-
-
-
-
搜索结果
37 条记录 (耗时 0.05 秒)
